Lloyd is the President & CEO of Repare Therapeutics (Nasdaq: RPTX), a clinical stage precision oncology company applying advanced genomics to novel therapeutics in development.

Prior to Repare, Lloyd was a Managing Partner with Persistence Capital Partners. He began his career with McKinsey & Company, and subsequently served as CEO of several emerging biotechnology companies including Advanced Bioconcept, Caprion Pharmaceuticals (now CellCarta), which he co-founded, and Thallion Pharmaceuticals.

He currently serves on the board of directors of Aktis Oncology (private). Lloyd previously served as Chairman of LMC Diabetes & Endocrinology and was Chairman of the Board of MedReleaf (TMX: LEAF), which was sold to Aurora Cannabis for $3.2 billion in 2018, and previously served on the boards of several public and private companies in the US and Canada. He was an Entrepreneur-in-Residence with Versant Ventures from 2016 to 2020.

Lloyd was honored in 2013 by the Financial Times as Outstanding Director of the Year for public companies.

Lloyd holds a B.A. in politics from Brandeis University and an M.B.A. from Harvard Business School.